Abstract:Metastasis is the main cause of death for patients with breast cancer. Many studies have characterized the genomic landscape of breast cancer during its early stages. However, there is evidence that genomic alterations are acquired during the evolution of cancers from their early to late stages, and that the genomic landscape of early cancers is not representative of that of lethal cancers<a href="#ref-CR1">1</a>,<a href="#ref-CR2">2</a>,<a href="#ref-CR3">3</a>,<a href="#ref-CR4">4</a>,<a href="#ref-CR5">5</a>,<a href="#ref-CR6">6</a>,<a href="/articles/s41586-019-1056-z#ref-CR7">7</a>. Here we investigated the landscape of somatic alterations in 617 metastatic breast cancers. Nine driver genes (TP53, ESR1, GATA3, KMT2C, NCOR1, AKT1, NF1, RIC8A and RB1) were more frequently mutated in metastatic breast cancers that expressed hormone receptors (oestrogen and/or progesterone receptors; HR+) but did not have high levels of HER2 (HER2−; n = 381), when compared to early breast cancers from The Cancer Genome Atlas. In addition, 18 amplicons were more frequently observed in HR+/HER2− metastatic breast cancers. These cancers showed an increase in mutational signatures S2, S3, S10, S13 and S17. Among the gene alterations that were enriched in HR+/HER2− metastatic breast cancers, mutations in TP53, RB1 and NF1, together with S10, S13 and S17, were associated with poor outcome. Metastatic triple-negative breast cancers showed an increase in the frequency of somatic biallelic loss-of-function mutations in genes related to homologous recombination DNA repair, compared to early triple-negative breast cancers (7% versus 2%). Finally, metastatic breast cancers showed an increase in mutational burden and clonal diversity compared to early breast cancers. Thus, the genomic landscape of metastatic breast cancer is enriched in clinically relevant genomic alterations and is more complex than that of early breast cancer. The identification of genomic alterations associated with poor outcome will allow earlier and better selection of patients who require the use of treatments that are still in clinical trials. The genetic complexity observed in advanced breast cancer suggests that such treatments should be introduced as early as possible in the disease course.

Multiple Primary Cancer: Genetic Pathomorphological Factors of Endometrial and Breast Cancer

Multiple Primary Cancers: Association of Breast Cancer and Lung Carcinoma

Breast cancer

Endometrial Cancer: Genetic, Metabolic Characteristics, Therapeutic Strategies and Nanomedicine

Triple Primary Cancers: An Analysis of Genetic and Environmental Factors

COMBINED TREATMENT OF PATIENTS WITH ENDOMETRIAL CANCER I-II (Т1-2N0M0) TAKING INTO ACCOUNT THE LEVEL OF EXPRESSION OF MOLECULAR BIOLOGICAL TUMOR MARKERS

A Comprehensive View over Breast Cancer Molecular Subtypes and to Provide Foundation for Treatment Strategy

Metastatic Trends in Breast Cancer According to Molecular Subtypes, Estrogen Receptor, Progesterone Receptor and Human Epidermal Growth Factor Receptor 2neu Status

Breast Cancer Tissue Markers, Genomic Profiling, and Other Prognostic Factors: A Primer for Radiologists

Gene Expression Modules in Primary Breast Cancers As Risk Factors for Organotropic Patterns of First Metastatic Spread: a Case Control Study

Clinical characterization and genomic landscape of gynecological cancers among patients attending a Chinese hospital

Breast cancer intratumour heterogeneity: current status and clinical implications

Unraveling the Multifaceted Nature of Breast Cancer: Harnessing the Power of Machine Learning and Statistical Models for In-depth Investigation, Prognosis, and Treatment Optimization

Genomic characterization of metastatic breast cancers

Breast Tumor Metastasis and Its Microenvironment: It Takes Both Seed and Soil to Grow a Tumor and Target It for Treatment

Multiple Primary Malignant Tumors - A Clinical Analysis of 15,321 Patients with Malignancies at a Single Center in China

Pathogenesis of Endometriosis and Endometriosis-Associated Cancers

Comprehensive analysis of gene expression profiles to identify differential prognostic factors of primary and metastatic breast cancer

Molecular Classification of Breast Carcinoma Based on the Prognostic Marker: A Clinico-pathological Correlation

Triple Negative Breast Cancer Profile, from Gene to microRNA, in Relation to Ethnicity

‘Breast Cancer Resistance Likelihood and Personalized Treatment Through Integrated Multiomics’